The State Department issued a waiver for lifesaving aid, but HIV clinics remain shut and uncertainty lingers over the future of PEPFAR, which has saved 25 million lives.

A U.S. humanitarian waiver will allow people in several countries to continue accessing life-saving HIV treatments, the UNAIDS said on Wednesday, after President Donald Trump's freeze on foreign aid threatened such supplies.

The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), according to The New York Times.

Uganda sought to dispel fears among HIV patients that a US aid freeze will interrupt treatment and promised that such programs will continue.

The Trump administration has moved to stop the supply of lifesaving drugs for HIV, malaria, and tuberculosis in countries supported by USAID around the globe.

As part of the foreign aid freeze by President Donald Trump, the U.S. distribution of HIV drugs in poor countries has been stopped.

A stop in all of PEPFAR’s work shuttered clinics this week. Then, a new exemption for “life-saving” treatment left organizations uncertain.

The President’s Emergency Plan for AIDS Relief (PEPFAR), a federal program that provides HIV medications, is one of the programs on pause during a 90-day review ordered by the Secretary of State.

Almost 1 in 10 patients receiving HIV care may have binge eating disorder (BED), a significantly higher rate than the 0.3% reported in the general population, according to a cross-sectional study. Individuals with possible BED were six times more likely than others to have clinical obesity and twice as likely to be overweight.

Almost 136,000 babies are expected to be born with HIV in the next three months, mostly in Africa, because of the Trump administration’s “stop work order” on foreign assistance, according to a top research foundation.

In patients with HIV, alcohol reduction after a 6-month intervention and adherence to isoniazid had no effect on the high levels of viral suppression reported at baseline.

Major barriers in screening for fatty liver disease in patients with HIV included uncertainties about testing, diagnostic data insufficiency, low priority, time constraints, and referral limitations.